Early Success: mRNA & CAR T Therapy To Treat Rare Autoimmune Disease Myasthenia Gravis
Medical innovation Chimeric Antigen Receptor T cell (CAR T) therapy has attracted attention in recent years for its ability to send difficult-to-treat blood cancers into remission—even curing cancer for a minority. Now, research suggests that the therapy could potentially be adapted to …
New Organ Models Open Up Avenues Of Research For Lung Disease
Lung diseases like emphysema or chronic obstructive pulmonary disease are a leading cause of death worldwide. With the advent of COVID-19, these diseases have only become more prevalent. Despite the severity of lung diseases, there are few available treatments that can alleviate …
Institutions, Fiscal Space, and Social Health Protection
Ensuring and managing the fiscal space is necessary for sustained government investment in human capital. As human capital complements physical capital in the ‘production’ of GDP, countries that can raise adequate resources for such investments experience higher growth in the long run. …
The Future Of Cancer Treatment? Treating Multiple Myeloma With MRNA-CAR T Technology
At the frontier of cancer treatment development, there is hope for two modern technologies to combine and achieve unprecedented results: messenger RNA and Chimeric Antigen Receptor T Cell Therapy. Biopharm company Cartesian Therapeutics is determined to use this unique platform to benefit …
New coalition formed to fight heart disease across Asia
On June 25, 2023, patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank came together to launch the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), a multisectoral coalition committed to improving heart health and reducing the CVD burden …
Cancer Treatment CAR T Therapy Prolongs Survival Over Standard Care
Newly released study results demonstrate that Yescarta, a CAR T therapy, prolongs survival longer than standard care for patients with early relapsed or refractory large diffuse B cell lymphoma. About the CAR T Therapy Chimeric Antigen Receptor T therapy is a cell …
No Pain, FAAH-OUT
Researchers from the University College London have brought us one step closer to understanding how we feel pain. Their study, published in Brain, describes a rare genetic mutation found in a patient who can feel no physical pain, anxiety, or fear. Joanne Cameron …
To Kill And Kill Again: How Cytotoxic T Cells Attack Target After Target
Cytotoxic T cells, also known as the “killer” T cells, provide the foundation for cell-based CAR T therapy. The therapy borrows and enhances the T cell’s ability to kill multiple targets in rapid succession. This way, the T cell destroys target after …
At Last, People Can Believe Your Pain
When visiting the doctor, one of the first questions patients are asked about their pain is, “How badly does it hurt on a scale from 0-10?”. While these pain ratings are a common method to help physicians diagnose chronic pain syndromes, they …
ACCESS Health Consultant’s Bereaved Caregivers Project Receives Seed Funding
ACCESS Health Southeast Asia Consultant Miguel Tan took part in the Design4Impact (D4I) challenge, an open platform inviting innovators to co-create sustainable community-owned solutions supported by the Ministry of Health Office for Healthcare Transformation. This year’s theme was “Uplifting Vulnerable Families in …
Recent Comments